Trouble Viewing This Email: Click Here

May 24, 2022

FOUNDING MEMBER OF

Linshom Medical, Inc. Closes $1.5 million Series A Round with Investment from Maryland Momentum Fund and Current Investors

Linshom is First to Deliver an Operating-Room-Quality Respiratory Profile to Patient Bedside for Continuous, Predictive Respiratory Monitoring (CPRM)

Baltimore, Md. (April 27, 2022) – Linshom (“to breathe”), a Maryland-based startup developing a respiratory monitoring system, closed a $1.5 million Series A funding round with investment from the Maryland Momentum Fund and current investors.

The Linshom Respiratory Sensor and Monitor is the first predictive, continuous respiratory monitoring system able to practically reach the patients’ bedside. Severe respiratory events can begin to cause brain damage only three minutes after breathing ceases. While critical care patients are continuously monitored for respiratory function, patients on general care floors are not monitored as closely, but are still at risk for serious respiratory complications. The Linshom Respiratory System bridges that gap, helping clinicians respond more quickly to severe respiratory-related events.

BHI Congratulates SISU Global!

Sisu Global is a 2022 TiE50 Winner! TiE50 is TiE Silicon Valley's premier annual awards program, contested by thousands of early to mid-stage startups worldwide.

"Sisu Global is grateful to be a part of the TiE50 community this year. We are looking forward to the opportunity of working together and our expansion into India." President & Co-founder, Gillian Henker

Visit the link in the comments below to learn more about TiE50.

Deka Biosciences - Daikine Platform Explanation

Dr. John Mumm explains the Diakine™ platform developed by Deka Biosciences.

How can your BioHealth business benefit from a review by BHI industry experts? Please register for our next Entrepreneur-In-Residence (EIR) day on June 20th and find out. To sign-up for any of the EIR dates in 2022, please follow this link.

These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and medical devices. If you’re a growth-stage biohealth company looking for unbiased advice on your pitch deck, commercialization strategy, evidence development or entrepreneurial challenges, our EIRs can help.

To sign-up for any of the EIR dates in 2022, please follow this link.

Maryland Stem Cell Research Commission Announces Over $7 Million in Awards to Accelerate Cures | TEDCO

May 16, 2022 (Columbia, Md.)—The Maryland Stem Cell Research Commission announced it will grant $7,067,409 in award funding to innovative research that will strengthen and advance stem cell treatments and technologies in Maryland. Awardees submitted proposals to the Commission in response to its Request for Applications (RFAs) for its second round of funding cycle in 2022.

Recipients include 24 scientists accelerating research at Johns Hopkins University, Britecyte, Inc., RenOVAte Biosciences, Inc., RoosterBio, Inc., and the University of Maryland, Baltimore.

Johns Hopkins neuroscientists find brain mechanism tied to age-related memory loss | Hub

Working with rats, neuroscientists at Johns Hopkins University have pinpointed a mechanism in the brain responsible for a common type of age-related memory loss. The work, published in Current Biology, sheds light on the workings of aging brains and may deepen our understanding of Alzheimer's disease and similar disorders in humans.

Image: https://hub.jhu.edu

SBIR Matching Fund | Technology Commercialization Office | The George Washington University

The GW TCO SBIR Matching Fund will help startups collaborate with GW researchers to develop innovations licensed from GW.

The first awards will be available in summer 2022. Applications from startups will be considered on a rolling basis and may now be submitted.

The GW TCO SBIR Matching Fund will provide up to $100K per award for internal GW research. It will match 2:1 the amount of research the applicant company has sponsored at GW in the last 2 years. Also included in the match are amounts the company is providing to GW as a subaward on a Phase I SBIR or STTR, which started in the last 2 years. The maximum award is $100,000. The scope of work is to further develop a technology licensed from GW TCO. Up to 2 GW TCO SBIR Matching Funds will be provided per fiscal year.

Image: https://commercialization.gwu.edu

Landscaping the DMV Region: A Hotbed for Innovation | by Michael Nestor | Bioeconomy.XYZ | Medium

If I asked you, “Where in the United States is biotechnology innovation occurring at a record pace, what states or cities come to mind? You probably thought of Boston, San Francisco, or even New York immediately.

These are not bad guesses, but what if I told you that the Washington, D.C./Maryland/Virginia (DMV) region is one of the country’s best places to engage in the biotechnology sector?

Image: Courtesy of the National Cancer Institute (via Unsplash)

The National Institutes of Health, a Technology Transfer Wellspring · BioBuzz

The National Institutes of Health (NIH) is a critical pillar of the U.S. public health system and a beacon of guidance for healthcare best practices across the globe. This has never been more evident than during the COVID-19 crisis.

A lesser-known NIH facet is its long and productive history of technology transfer success.

What is a pre-IND? Why have a pre-IND? What goes into preparing for a pre-IND? And, what documents are required? All of these questions and more will be answered in this webinar presented by Dr. Carmella Moody, a regulatory affairs specialist at RTI International. Dr. Carmella Moody brings her expertise in regulatory affairs and the development of small molecules to the Catalyze program, where she serves as a technical project lead. In this 1-hour webinar, Dr. Moody will explain the process of preparing and approaching an effective pre-IND meeting, but also what to expect from FDA feedback and how to incorporate it into your project to ultimately save time and money.

ARMI Seeks: Director, Education and Workforce Development - Manchester, NH - Advanced Regenerative Manufacturing Institute Inc Jobs

The Advanced Regenerative Manufacturing Institute ("ARMI") is focused on empowering the U.S. regenerative medicine industry to bring new life-saving products to market by lowering the barriers to manufacturing. Our goal is to improve lives by restoring or replacing the function of damaged cells, tissues, and organs for patients. BioFabUSA's mission is to develop a highly diverse, competitive, capable and innovative cell, tissue, and organ ecosystem that ensures a low-cost and high-quality domestic healthcare system, and domestic leadership in the biofabrication industrial base.

The Real Estate Problem Holding Back NYC's Life Sciences Industry

Life sciences in New York City is poised for growth, but industry leaders said that will only be assured if developers build enough spaces for startups of all sizes. Unless the city can accommodate life sciences companies in their earlier years, when they need less space, experts warn NYC could lose talent to rival life sciences hubs.

Image: Bisnow/Ellie Meyer
Outshine Properties' Bill Hunter, New York Economic Development Corp.'s Susan Rosenthal, Hunter Roberts Construction Group's Brian Aronne, Nan Fung Life Sciences' Matt Powers and SGA's Brooks Slocum.